

# Giulia Martini

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9140866/publications.pdf>

Version: 2024-02-01

32  
papers

1,030  
citations

759233

12  
h-index

477307

29  
g-index

32  
all docs

32  
docs citations

32  
times ranked

1261  
citing authors

#	ARTICLE	IF	CITATIONS
1	Which treatment after first line therapy in NSCLC patients without genetic alterations in the era of immunotherapy?. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 169, 103538.	4.4	13
2	Immunotherapy for Biliary Tract Cancer in the Era of Precision Medicine: Current Knowledge and Future Perspectives. <i>International Journal of Molecular Sciences</i> , 2022, 23, 820.	4.1	15
3	Multi-Omic Approaches in Colorectal Cancer beyond Genomic Data. <i>Journal of Personalized Medicine</i> , 2022, 12, 128.	2.5	6
4	Encorafenib, cetuximab, and cytotoxic chemotherapy combinations in BRAFV600E CRC murine models.. <i>Journal of Clinical Oncology</i> , 2022, 40, 145-145.	1.6	0
5	Anti-tumor activity of cetuximab plus avelumab in non-small cell lung cancer patients involves innate immunity activation: findings from the CAVE-Lung trial. <i>Journal of Experimental and Clinical Cancer Research</i> , 2022, 41, 109.	8.6	7
6	Immunotherapy for head and neck cancer: Present and future. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 174, 103679.	4.4	45
7	Cancer cells adapt FAM134B/BiP mediated ER-phagy to survive hypoxic stress. <i>Cell Death and Disease</i> , 2022, 13, 357.	6.3	15
8	Mixed Neuroendocrine Non-Neuroendocrine Neoplasms of the Gastrointestinal Tract: A Case Series. <i>Healthcare (Switzerland)</i> , 2022, 10, 708.	2.0	4
9	Gut microbiota correlates with antitumor activity in patients with <scp>mCRC</scp> and <scp>NSCLC</scp> treated with cetuximab plus avelumab. <i>International Journal of Cancer</i> , 2022, 151, 473-480.	5.1	24
10	Clinical management of metastatic colorectal cancer in the era of precision medicine. <i>Ca-A Cancer Journal for Clinicians</i> , 2022, 72, 372-401.	329.8	167
11	Vulnerability to low-dose combination of irinotecan and niraparib in ATM-mutated colorectal cancer. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 15.	8.6	13
12	Dual inhibition of TGF $\beta$ 2 and AXL as a novel therapy for human colorectal adenocarcinoma with mesenchymal phenotype. <i>Medical Oncology</i> , 2021, 38, 24.	2.5	7
13	Biomarker-Guided Anti-EGFR Rechallenge Therapy in Metastatic Colorectal Cancer. <i>Cancers</i> , 2021, 13, 1941.	3.7	21
14	Final results from the CAVE (cetuximab rechallenge plus avelumab) mCRC phase II trial: Skin toxicity as a predictor of clinical activity.. <i>Journal of Clinical Oncology</i> , 2021, 39, 3578-3578.	1.6	6
15	Cetuximab Rechallenge Plus Avelumab in Pretreated Patients With <i>RAS</i> Wild-type Metastatic Colorectal Cancer. <i>JAMA Oncology</i> , 2021, 7, 1529.	7.1	80
16	How Immunotherapy Has Changed the Continuum of Care in Hepatocellular Carcinoma. <i>Cancers</i> , 2021, 13, 4719.	3.7	7
17	Retrospective Study of Regorafenib Versus TAS-102 Efficacy and Safety in Chemorefractory Metastatic Colorectal Cancer (mCRC) Patients: A Multi-institution Real Life Clinical Data. <i>Clinical Colorectal Cancer</i> , 2021, 20, 227-235.	2.3	10
18	The Evolving Role of Consensus Molecular Subtypes: a Step Beyond Inpatient Selection for Treatment of Colorectal Cancer. <i>Current Treatment Options in Oncology</i> , 2021, 22, 113.	3.0	9

#	ARTICLE	IF	CITATIONS
19	Skin Toxicity as Predictor of Survival in Refractory Patients with RAS Wild-Type Metastatic Colorectal Cancer Treated with Cetuximab and Avelumab (CAVE) as Rechallenge Strategy. <i>Cancers</i> , 2021, 13, 5715.	3.7	6
20	AXL is a predictor of poor survival and of resistance to anti-EGFR therapy in RAS wild-type metastatic colorectal cancer. <i>European Journal of Cancer</i> , 2020, 138, 1-10.	2.8	23
21	Feasibility of next-generation sequencing in clinical practice: results of a pilot study in the Department of Precision Medicine at the University of Campania "Luigi Vanvitelli". <i>ESMO Open</i> , 2020, 5, e000675.	4.5	11
22	Resistance to anti-epidermal growth factor receptor in metastatic colorectal cancer: What does still need to be addressed?. <i>Cancer Treatment Reviews</i> , 2020, 86, 102023.	7.7	34
23	Patient and tumor characteristics as determinants of overall survival (OS) in BRAF V600 mutant (mt) metastatic colorectal cancer (mCRC) treated with doublet or triplet targeted therapy.. <i>Journal of Clinical Oncology</i> , 2020, 38, 4112-4112.	1.6	6
24	The predictive role of plasma mutant allele fraction to antiangiogenic drugs in patients with mCRC: An expanded analysis of surrogate biomarkers of response to first-line treatment with bevacizumab.. <i>Journal of Clinical Oncology</i> , 2020, 38, 3541-3541.	1.6	0
25	Clinical Practice Use of Liquid Biopsy to Identify RAS/BRAF Mutations in Patients with Metastatic Colorectal Cancer (mCRC): A Single Institution Experience. <i>Cancers</i> , 2019, 11, 1504.	3.7	36
26	Receptor tyrosine kinase-dependent PI3K activation is an escape mechanism to vertical suppression of the EGFR/RAS/MAPK pathway in KRAS-mutated human colorectal cancer cell lines. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 41.	8.6	57
27	Immunotherapy of colorectal cancer: Challenges for therapeutic efficacy. <i>Cancer Treatment Reviews</i> , 2019, 76, 22-32.	7.7	224
28	How I treat anal squamous cell carcinoma. <i>ESMO Open</i> , 2019, 4, e000711.	4.5	4
29	Present and future of metastatic colorectal cancer treatment: A review of new candidate targets. <i>World Journal of Gastroenterology</i> , 2017, 23, 4675.	3.3	91
30	Therapeutic value of EGFR inhibition in CRC and NSCLC: 15 years of clinical evidence. <i>ESMO Open</i> , 2016, 1, e000088.	4.5	85
31	Phase III study of regorafenib versus placebo as maintenance therapy in RAS wild type metastatic colorectal cancer (RAVELLO trial).. <i>Journal of Clinical Oncology</i> , 2015, 33, TPS3634-TPS3634.	1.6	2
32	Phase III study of regorafenib versus placebo as maintenance therapy in RAS wild type metastatic colorectal cancer (RAVELLO trial).. <i>Journal of Clinical Oncology</i> , 2015, 33, TPS789-TPS789.	1.6	2